Founded in Feb 2020, Hera Biotech is developing the world’s first non-surgical test capable of both staging and diagnosing endometriosis. Hera’s test, MetriDxTM will take diagnostic capability out of the operating room and place it directly into the hands of physicians treating these patients. MetriDxTM will revolutionize the way that women with endometriosis experience diagnosis, drastically reduce time to diagnosis, and enable informed clinical management of the disease. Hera Biotech’s core technology was developed by scientists from UT San Antonio. Hera has been the recipient of a number of non-dilutive funding, including a grant from The Endometriosis Foundation of America. Hera was the winner of the Kendra Scott Pitch Competition, the Health Wildcatters and MedVentures Deal Day Pitch competition, and a top 3 in Ignite Fire Pitch Competition and the San Diego Angel Conference.

Founder

Somer Baburek is an experienced leader in life science start-ups, including Rx drug development, clinical operations, FDA regulation, and achieving successful exit. Somer spent 7 years as the Director of Clinical Ops for Santalis Pharmaceuticals (founded by Paul), and worked as a consultant to Target Technology Funds (venture fund run by Paul) for 7 years.

​

Hera’s website here.

HQ: San Antonio, TX

Industry: Healthcare

Vertical: Endometriosis